Mylan’s Agila acquisition cleared but India mulls controls on domestic deals
This article was originally published in Scrip
Executive Summary
Mylan's $1.6bn-plus acquisition of Strides Arcolab's injectables arm, Agila Specialties, has finally been cleared by India's Foreign Investment Promotion Board (FIPB), although experts believe that the days of unfettered foreign direct investment (FDI) transactions in the Indian pharmaceutical sector may be over, especially if they concern domestic formulations businesses.